ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Pacific Biosciences of California, Inc." (PACB) Report Updated: May 04, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Pacific Biosciences of California, Inc." (PACB)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Life Sciences Tools & Services
Competitors:

Stock Analysis

Rating: Monthly View

A
B
C
D
F
May June July August September October November December January February March April

Rating: Weekly View

This Week: B down downgrade
Last Week: A same upgrade
Two Weeks Ago: B up no change
service keys

"Pacific Biosciences of California, Inc."© quotemedia

Company Profile

Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company provides single molecule real-time (SMRT) technology platform, which enables single molecule real-time detection of biological processes. It offers PacBio RS II high resolution genetic analyzer, an instrument that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company provides consumable products, which include sealed and packaged SMRT Cells, as well as various reagent kits, such as template preparation kits, binding kits, and sequencing kits to run the PacBio RS II. Its customers include research institutions, commercial laboratories, genome centers, clinical, government and academic institutions, genomics service providers, pharmaceutical companies, and agricultural companies. The company markets its products through a direct sales force in North America and Europe as well as primarily through distributors in Asia. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.